{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:35:31Z","timestamp":1791992131516,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015048","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000}}],"reference-count":272,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015048.pub2","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T10:38:47Z","timestamp":1664188727000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery"],"prefix":"10.1002","volume":"2022","author":[{"given":"Andrew","family":"Bryant","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Hiu","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience T","family":"Kunonga","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketankumar","family":"Gajjar","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; 1st Floor Maternity Unit, City Hospital Campus; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A","family":"Winter-Roach","sequence":"additional","affiliation":[{"name":"The Department of Surgery; Christie Hospital NHS Foundation Trust; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elattar","sequence":"additional","affiliation":[{"name":"City Hospital & Birmingham Treatment Centre; Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Naik","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology; Northern Gynaecological Oncology Centre; Gateshead UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.2001.6172","article-title":"Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study","volume":"81","author":"Akahira","year":"2001","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"77\u201385","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2005.08.027","article-title":"Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer","volume":"100","author":"Aletti","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jamcollsurg.2006.06.027","article-title":"Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer","volume":"203","author":"Aletti","year":"2006","journal-title":"Journal of the American College of Surgeons"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","article-title":"Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV","volume":"140","author":"Ataseven","year":"2016","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"530\u20134","DOI":"10.1016\/j.ygyno.2019.12.016","article-title":"Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer","volume":"156","author":"Bixel","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2011.04.047","article-title":"Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center","volume":"122","author":"Bristow","year":"2011","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0009|cit9","first-page":"156","article-title":"Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?","volume":"102","author":"Chan","year":"2003","journal-title":"Obstetrics and Gynecology"},{"issue":"13","key":"10.1002\/14651858.CD015048.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Annals of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2012.05.014","article-title":"Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer","volume":"126","author":"Chang","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"559\u201364","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0300891618792468","article-title":"Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age","volume":"105","author":"Cioffi","year":"2018","journal-title":"Tumori Journal"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jog.13663","article-title":"Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin\/paclitaxel chemotherapy","volume":"44","author":"Cuylan","year":"2018","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Davidson BA Broadwater G Crim A Boccacio R Bixel K Backes F Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy Gynecologic Oncology 2019 152 3 554 9","DOI":"10.1016\/j.ygyno.2018.12.011"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2016.04.016","article-title":"Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer","volume":"141","author":"Feng","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","article-title":"The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study","volume":"131","author":"Hofstetter","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3802\/jgo.2015.26.4.303","article-title":"Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients","volume":"26","author":"Iwase","year":"2015","journal-title":"Journal of Gynecologic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015048.pub2-BIB0023|cit23","first-page":"1163","article-title":"Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer","volume":"39","author":"Kaban","year":"2017","journal-title":"Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1245\/s10434-017-6079-9","article-title":"Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer","volume":"24","author":"Kahl","year":"2017","journal-title":"Annals of Surgical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD015048.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","article-title":"Addition of epirubicin as a third drug to carboplatin\/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens","volume":"24","author":"du Bois","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD015048.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois A","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2016.07.014","article-title":"Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO","volume":"66","author":"Klar","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"15","key":"10.1002\/14651858.CD015048.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2011.06.031","article-title":"Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization","volume":"123","author":"Langstraat","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"64\u201372","DOI":"10.1016\/j.ejogrb.2019.12.001","article-title":"Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN)","volume":"245","author":"Lecointre","year":"2020","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0033|cit33","first-page":"v415","article-title":"1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study","volume":"30","author":"Lecuru","year":"2019","journal-title":"Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain"},{"issue":"36","key":"10.1002\/14651858.CD015048.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e22100","DOI":"10.1097\/MD.0000000000022100","article-title":"Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0035|cit35","first-page":"647","article-title":"Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study","volume":"26","author":"Lorusso","year":"2016","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1092\u20139","DOI":"10.1111\/aogs.13835","article-title":"Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer","volume":"99","author":"Luger","year":"2020","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study","volume":"13","author":"McGuire","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2017.08.003","article-title":"Associations between residual disease and survival in epithelial ovarian cancer by histologic type","volume":"14","author":"Melamed","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2017.08.003","article-title":"Associations between residual disease and survival in epithelial ovarian cancer by histologic type","volume":"14","author":"Melamed","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3802\/jgo.2018.29.e13","article-title":"Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer","volume":"29","author":"Paik","year":"2018","journal-title":"Journal of Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2010.07.032","article-title":"Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes","volume":"119","author":"Peiretti","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygyno.2012.04.030","article-title":"Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes","volume":"126","author":"Peiretti","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"European Journal of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/IGC.0b013e31823de6ae","article-title":"Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data","volume":"22","author":"Polterauer","year":"2012","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"502\u20137","DOI":"10.1007\/s10147-019-01567-y","article-title":"Dose\u2011dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study","volume":"25","author":"Shibutani","year":"2020","journal-title":"International Journal of Clinical Oncology"},{"issue":"S1","key":"10.1002\/14651858.CD015048.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2016.04.148","article-title":"Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer","volume":"141","author":"Shim","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1245\/s10434-013-3278-x","article-title":"Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum\/taxane-based chemotherapy and late interval debulking surgery","volume":"21","author":"Stoeckle","year":"2014","journal-title":"Annals of Surgical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1525-1438.1996.06030219.x","article-title":"The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma","volume":"6","author":"Van Geene","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)","volume":"17","author":"Wimberger","year":"2010","journal-title":"Annals of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"18","author":"Muggia","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD015048.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015048.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD015048.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"18","author":"Muggia","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015048.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1002\/14651858.CD015048.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1200\/JCO.2006.10.3846","article-title":"Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Spriggs","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015048.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/jog.13710","article-title":"Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients","volume":"44","author":"Zhang","year":"2018","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"issue":"11","key":"10.1002\/14651858.CD015048.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00432-016-2228-y","article-title":"The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study","volume":"142","author":"Zhu","year":"2016","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015048.pub2-BIB0068|cit68","first-page":"618","article-title":"Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study","volume":"71","author":"Alberts","year":"1993","journal-title":"Cancer"},{"issue":"26","key":"10.1002\/14651858.CD015048.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ygyno.2006.06.019","article-title":"Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer","volume":"103","author":"Alphs","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1701-2163(16)35272-0","article-title":"Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery","volume":"34","author":"Altman","year":"2012","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2005.07.121","article-title":"The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark","volume":"99","author":"Andersen","year":"2005","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/0284186X.2015.1054950","article-title":"Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer\u2013a population-based study","volume":"55","author":"Anuradha","year":"2016","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ijgc-00009577-200602001-00004","article-title":"Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998","volume":"1","author":"Bailey","year":"2006","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1097-0142(19940715)74:2<656::AID-CNCR2820740218>3.0.CO;2-6","article-title":"Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma","volume":"74","author":"Baker","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ajog.2003.09.073","article-title":"Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study","volume":"190","author":"Barda","year":"2004","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/0029-7844(95)00494-7","article-title":"The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma","volume":"87","author":"Benedetti-Panici","year":"1996","journal-title":"Obstetrics & Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0090-8258(90)90042-J","article-title":"Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study","volume":"38","author":"Bertelsen","year":"1990","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/gyno.1993.1081","article-title":"A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA)","volume":"49","author":"Bertelsen","year":"1993","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00404-015-3813-z","article-title":"Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer","volume":"293","author":"Bian","year":"2016","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.1999.17.3.767","article-title":"Natural history of stage IV epithelial ovarian cancer [see comment]","volume":"17","author":"Bonnefoi","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1525-1438.1996.06020108.x","article-title":"In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features","volume":"6","author":"Brinkhuis","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1525-1438.1996.06030168.x","article-title":"Quantitative pathological variables as prognostic factors for overall survival in Danish patients with FIGO stage III ovarian cancer","volume":"6","author":"Brinkhuis","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1998.5145","article-title":"Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer","volume":"72","author":"Bristow","year":"1999","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.clon.2007.06.015","article-title":"The role of bowel surgery with cytoreduction for epithelial ovarian cancer","volume":"19","author":"Cai","year":"2007","journal-title":"Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study","volume":"29","author":"Ceresoli","year":"2018","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0087|cit87","unstructured":"Chekman C Layoune R Hocine O Raissi N Ferhat HA Ali Khodja H An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015; 2015 Oct 24-27; Nice, France 2015 1316"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Clamp AR McNeish IA Dean A Gallardo-Rincon D Kim JW O'Donnell DM Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma (EOC) treatment Annals of Oncology 2018 viii336","DOI":"10.1093\/annonc\/mdy285.151"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000421-199710000-00019","article-title":"Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide","volume":"20","author":"Colozza","year":"1997","journal-title":"American Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1991.9.4.658","article-title":"Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma","volume":"9","author":"Conte","year":"1991","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JCO.1996.14.2.351","article-title":"High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest","volume":"14","author":"Conte","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD015048.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial","volume":"23","author":"Crawford","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0090-8258(90)90244-F","article-title":"A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"39","author":"Creasman","year":"1990","journal-title":"Gynecologic Oncology"},{"issue":"S1","key":"10.1002\/14651858.CD015048.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1017\/S0266462319003428","article-title":"VP100 Ultraradical ovarian cancer surgery comparative clinical effectiveness","volume":"35","author":"Cummins","year":"2019","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/gyno.1994.1082","article-title":"Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment","volume":"53","author":"Del Campo","year":"1994","journal-title":"Gynecologic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0097|cit97","first-page":"323","article-title":"Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study","volume":"11","author":"Oliveira","year":"1990","journal-title":"European Journal of Gynaecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/gyno.1996.0249","article-title":"Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases","volume":"62","author":"di Re","year":"1996","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"e17042","DOI":"10.1200\/JCO.2019.37.15_suppl.e17042","article-title":"Prognostic implications of lymph node metastasis in advanced ovarian cancer: analysis of the National Cancer Database 2006 to 2014","volume":"0","author":"Elgamal","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD015048.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"issue":"15","key":"10.1002\/14651858.CD015048.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2018.36.15_suppl.5516","article-title":"Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0103|cit103","first-page":"309","article-title":"A study of prognostic factors of stage IV epithelial ovarian cancer [Chinese]","volume":"32","author":"Gao","year":"2001","journal-title":"Journal of West China University of Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1245\/s10434-015-4959-4","article-title":"Lymph node involvement pattern and survival differences of FIGO IIIC and FIGO IIIA1 ovarian cancer patients after primary complete tumor debulking surgery: a 10-year retrospective analysis of the tumor bank ovarian cancer network","volume":"23","author":"Gasimli","year":"2016","journal-title":"Annals of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0105|cit105","first-page":"165","article-title":"HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up","volume":"25","author":"Geisler","year":"2004","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0090-8258(89)90636-7","article-title":"Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide","volume":"32","author":"Gershenson","year":"1989","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0090-8258(92)90067-S","article-title":"The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: maintenance therapy reconsidered","volume":"47","author":"Gershenson","year":"1992","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/gyno.1995.1241","article-title":"Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer","volume":"58","author":"Gershenson","year":"1995","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2016.01.025","article-title":"Primary surgical cytoreduction in advanced ovarian cancer: an outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group","volume":"140","author":"Greggi","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1200\/JCO.1991.9.10.1793","article-title":"Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study","volume":"9","author":"Grem","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1990.8.3.502","article-title":"High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma","volume":"8","author":"Hainsworth","year":"1990","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-8258(92)90305-3","article-title":"Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma","volume":"45","author":"Hakes","year":"1992","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0003-3944(01)00661-7","article-title":"Interest of intestinal resection for treatment of advanced ovarian carcinoma","volume":"127","author":"Hamid","year":"2002","journal-title":"Annales de Chirurgie"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.annonc.a057876","article-title":"Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma","volume":"2","author":"Hardy","year":"1991","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2016.03.015","article-title":"Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery","volume":"141","author":"Heitz","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/gyno.1996.0334","article-title":"\"MECCA\": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer","volume":"63","author":"Hoskins","year":"1996","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1525-1438.7.s1.5.x","article-title":"Combination paclitaxel (Taxol(R))-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer","volume":"7","author":"Hoskins","year":"1997","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0119|cit119","first-page":"281","article-title":"Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary","volume":"100","author":"Itamochi","year":"2002","journal-title":"Obstetrics & Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/ijgc-00009577-200511000-00003","article-title":"Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?","volume":"15","author":"Kaern","year":"2005","journal-title":"International Journal of Gynecological Cancer"},{"issue":"9990","key":"10.1002\/14651858.CD015048.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD015048.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"Abstract 5500","DOI":"10.1200\/jco.2013.31.15_suppl.5500","article-title":"Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial","volume":"31 Suppl","author":"Kehoe","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0123|cit123","unstructured":"Kehoe S Wheeler S CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma www.ctu.mrc.ac.uk\/plugins\/StudyDisplay\/protocols\/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http:\/\/www.ctu.mrc.ac.uk\/research_areas\/study_details.aspx?s=9"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0124|cit124","unstructured":"Law K Murray C Kehoe S CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK 2006 90"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2016.12.017","article-title":"Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer","volume":"144","author":"Kessous","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00432-015-2055-6","article-title":"Integrated care in ovarian cancer \u201cIgV Ovar\u201d: results of a German pilot for higher quality in treatment of ovarian cancer","volume":"142","author":"Keyver-Paik","year":"2016","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecologic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015048.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/0959-8049(95)00274-M","article-title":"A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma","volume":"31","author":"Kristensen","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/gyno.1997.4839","article-title":"Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?","volume":"67","author":"Le","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ijgo.12653","article-title":"Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"143","author":"Lee","year":"2018","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0132|cit132","unstructured":"Fumarulo VV Loizzi V Cormio G Murgia F Vecchio V Minicucci V Neoadjuvant chemotherapy in advanced ovarian cancer: a single institution experience and a review of the literature International Journal of Gynecological Cancer 2016 1 1193"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000447743","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: a single-institution experience and a review of the literature","volume":"91","author":"Loizzi","year":"2016","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/gyno.1997.4913","article-title":"Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study","volume":"68","author":"Lorusso","year":"1998","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1525-1438.1998.97110.x","article-title":"Continuous infusion of ifosfamide and cisplatin as first-line therapy of patients with suboptimally debulked stage III\/IV epithelial ovarian cancer","volume":"8","author":"Malik","year":"1998","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/gyno.1993.1091","article-title":"Treatment of advanced ovarian carcinoma in the elderly","volume":"49","author":"Marchetti","year":"1993","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD015048.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000238673","article-title":"A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer","volume":"35","author":"Ngan","year":"1989","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"7","author":"Omura","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jjco\/hym145","article-title":"Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602","volume":"38","author":"Onda","year":"2008","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","article-title":"Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602","volume":"64","author":"Onda","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0144|cit144","doi-asserted-by":"crossref","unstructured":"Onda T Satoh T Saito T Kasamatsu T Nakanishi T Takehara K Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602 Journal of Clinical Oncology 2018 36 15 Suppl","DOI":"10.1200\/JCO.2018.36.15_suppl.5500"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1525-1438.1992.02060301.x","article-title":"Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer","volume":"2","author":"Palmer","year":"1992","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jso.2930480108","article-title":"Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery","volume":"48","author":"River","year":"1991","journal-title":"Journal of Surgical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015048.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/IGC.0000000000001286","article-title":"Surgical efforts might mitigate difference in response to neoadjuvant chemotherapy in stage IIIC\u2013IV unresectable ovarian cancer: a case-control multi-institutional study","volume":"28","author":"Raspagliesi","year":"2018","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.1986.4.4.515","article-title":"Prognostic factors in advanced ovarian carcinoma","volume":"4","author":"Redman","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/IGC.0b013e3182606ecb","article-title":"Positron emission tomography\/computed tomography predictors of overall survival in stage IIIC\/IV ovarian cancer","volume":"22","author":"Risum","year":"2012","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2013.06.017","article-title":"Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG)","volume":"130","author":"Rodriguez","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015048.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2016.04.526","article-title":"Obesity is a key prognostic factor in stage IIIC-IV ovarian cancer diagnosed prior to 65 years of age: a 10-year survival analysis","volume":"141","author":"Ruscito","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2014.07.099","article-title":"Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer","volume":"35","author":"Rutten","year":"2014","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0154|cit154","first-page":"8","article-title":"Prognostic model for survival of epithelial ovarian cancer patients treated with primary or interval debulking surgery","volume":"23","author":"Rutten","year":"2013","journal-title":"InInternational Journal Of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2007.08.003","article-title":"Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study","volume":"107","author":"Salani","year":"2007","journal-title":"Gynecologic Oncology"},{"issue":"18 Suppl A","key":"10.1002\/14651858.CD015048.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0305-7372(91)90023-S","article-title":"Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results","volume":"18","author":"Sessa","year":"1991","journal-title":"Cancer Treatment Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015048.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1980::AID-CNCR14>3.0.CO;2-O","article-title":"Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer","volume":"83","author":"Shapiro","year":"1998","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1555::AID-CNCR17>3.0.CO;2-4","article-title":"High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients","volume":"85","author":"Shinozuka","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0959-8049(95)00537-4","article-title":"Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Co-operative Oncology Group study","volume":"32","author":"Skarlos","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2015.08.005","article-title":"Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving?","volume":"139","author":"Smits","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0162|cit162","first-page":"847","article-title":"Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?","volume":"20","author":"Solmaz","year":"2015","journal-title":"Journal of Balkan Union of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijgo.12315","article-title":"Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer","volume":"193","author":"Son","year":"2017","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015048.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2015.01.100","article-title":"Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy","volume":"137","author":"Stewart","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1503\/cjs.014315","article-title":"The optimal time for surgery in women with serous ovarian cancer","volume":"59","author":"Stewart","year":"2016","journal-title":"Canadian Journal of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/ijgc-00009577-199609000-00011","article-title":"Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease","volume":"6","author":"Strauss","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/IGC.0000000000000389","article-title":"Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer","volume":"25","author":"Suidan","year":"2015","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0168|cit168","first-page":"625","article-title":"Therapeutic strategy in the management of stage II - IV epithelial ovarian carcinoma","volume":"113","author":"Sun","year":"2000","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.1989.7.2.223","article-title":"Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma","volume":"7","author":"Sutton","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0170|cit170","first-page":"1301","article-title":"Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary","volume":"16","author":"Takano","year":"2006","journal-title":"Oncology Reports"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10147-007-0670-1","article-title":"Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis","volume":"12","author":"Takano","year":"2007","journal-title":"International Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ijgc-00009577-199601000-00007","article-title":"An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum-cyclophosphamide chemotherapy in Singapore","volume":"6","author":"Tay","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1994.12.10.2066","article-title":"Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer","volume":"12","author":"Taylor","year":"1994","journal-title":"Journal Of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0174|cit174","first-page":"499","article-title":"The effect of centralization of primary surgery on survival in ovarian cancer patients","volume":"102","author":"Tingulstad","year":"2003","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s101470300016","article-title":"Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma","volume":"8","author":"Todo","year":"2003","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0176|cit176","unstructured":"Trhl\u00edk M Soumarov\u00e1 R Barto\u0161 P Kol\u00e1\u010dek J Horov\u00e1 I T\u011b\u017ek\u00e1 M Neoadjuvant chemotherapy for primary advanced ovarian cancer Biomedical Papers 2013 S98"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.04.037","article-title":"Treatment patterns by decade of life in elderly women ([greater-than or equal to]70 years of age) with ovarian cancer","volume":"98","author":"Uyar","year":"2005","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/gyno.1997.4845","article-title":"Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer","volume":"67","author":"Vallejos","year":"1997","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ijgc-00009577-199609001-00007","article-title":"The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study","volume":"6","author":"Van Der Burg","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015048.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2017.35.15_suppl.5519","article-title":"A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer","volume":"35","author":"Van Driel","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejogrb.2015.06.013","article-title":"Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital","volume":"192","author":"Vliet","year":"2015","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0182|cit182","first-page":"S620","article-title":"Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy","volume":"21","author":"Greimel","year":"2011","journal-title":"International Journal of Gynaecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2013.08.014","article-title":"Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy","volume":"131","author":"Greimel","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015048.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","article-title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","volume":"47","author":"Vergote","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0186|cit186","unstructured":"Vergote I Pecorelli S Stuart G Intergroup Study (EORTC 55971\/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma Trial protocol: http:\/\/www.cancer.gov\/clinicaltrials\/EORTC-55971"},{"issue":"31","key":"10.1002\/14651858.CD015048.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2011.36.9785","article-title":"Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer","volume":"29","author":"Vergote","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2010.08.008","article-title":"Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971\/NCIC-CTG OV13 neoadjuvant trial","volume":"47","author":"Verleye","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015048.pub2-BIB0190|cit190","first-page":"24","article-title":"Meta-analysis of the randomized EORTC and chorus neoadjuvant versus primary debulking trials in advanced tubo-ovarian cancer","volume":"26","author":"Vergote","year":"2016","journal-title":"International Journal of Gynecological Cancer"},{"issue":"12","key":"10.1002\/14651858.CD015048.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015048.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"e0147787","DOI":"10.1371\/journal.pone.0147787","article-title":"Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?","volume":"11","author":"Vidal","year":"2016","journal-title":"PlOS One"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0","article-title":"Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results\u00a0-\u00a0Eastern Cooperative Oncology Group study E2878","volume":"77","author":"Wadler","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2017.01.029","article-title":"Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible","volume":"145","author":"Wallace","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bjc.1995.539","article-title":"Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials","volume":"72","author":"Warwick","year":"1995","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1525-1438.1992.02050236.x","article-title":"Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis","volume":"2","author":"Willemse","year":"1992","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015048.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000226801","article-title":"Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center","volume":"47","author":"Wils","year":"1990","journal-title":"Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.pas.0000249449.13466.3c","article-title":"Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics","volume":"31","author":"Yamamoto","year":"2007","journal-title":"American Journal of Surgical Pathology"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0201|cit201","first-page":"449","article-title":"Cytoreductive surgery for stage IV epithelial ovarian cancer","volume":"18","author":"Zang","year":"1999","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00404-015-3704-3","article-title":"Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer","volume":"292","author":"Zhang","year":"2015","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012643.pub3","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","author":"Aldin","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0204|cit204","first-page":"676","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"187","author":"Aletti","year":"2007","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0207|cit207","unstructured":"BGCS https:\/\/www.bgcs.org.uk\/wp-content\/uploads\/2019\/05\/BGCS-Guidelines-Ovarian-Guidelines-2017.pdf 2017"},{"issue":"9","key":"10.1002\/14651858.CD015048.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bjc.2012.376","article-title":"Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review","volume":"107","author":"Borley","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2009.08.025","article-title":"Impact of surgeon and hospital ovarian cancer surgical case volume on in hospital mortality and related short-term outcomes","volume":"115","author":"Bristow","year":"2009","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"493\u20138","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","author":"Coleridge","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD015048.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"672\u2013705","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jrsm.1266","article-title":"Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests","volume":"9","author":"Debray","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0217|cit217","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition)","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1234\u201344","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3802\/jgo.2018.29.e47","article-title":"Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study","volume":"29","author":"Elzarkaa","year":"2018","journal-title":"Journal of Gynecologic Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015048.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study","volume":"51","author":"Sant","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"20","key":"10.1002\/14651858.CD015048.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2020.07.009","article-title":"Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population","volume":"159","author":"Falconer","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015048.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2019.37.15_suppl.5512","article-title":"Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study","volume":"37","author":"Ferron","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2020.01.010","article-title":"Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: a survival analysis","volume":"157","author":"Ghirardi","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1525-1438.1996.06020081.x","article-title":"Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate","volume":"1","author":"Girling","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0228|cit228","doi-asserted-by":"crossref","unstructured":"(GLOBOCAN 2018) Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians. Available from: http:\/\/gco.iarc.fr\/today\/home 2018 68 394-424 10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0231|cit231","first-page":"1014","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","year":"1975","journal-title":"Journal of the National Cancer Institute Monographs"},{"issue":"7650","key":"10.1002\/14651858.CD015048.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"170","author":"Hoskins","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"In Press","key":"10.1002\/14651858.CD015048.pub2-BIB0235|cit235","article-title":"Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer","author":"Hui","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0002-9378(92)91658-W","article-title":"Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?","volume":"166","author":"Hunter","year":"1992","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"https:\/\/doi.org","DOI":"10.1093\/jnci\/djx030","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132014, Featuring Survival Cancer Statistics","volume":"109","author":"Jemal","year":"2017","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2478\/raon-2018-0030","article-title":"Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals","volume":"52","author":"Kobal","year":"2018","journal-title":"Radiology and Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2017.07.126","article-title":"Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer","volume":"147","author":"Kumar","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"American Journal of Surgical Pathology"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extra ovarian origin of epithelial ovarian cancer-shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Human Pathology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0242|cit242","volume-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014"},{"issue":"6","key":"10.1002\/14651858.CD015048.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"745-54","DOI":"10.1634\/theoncologist.2015-0239","article-title":"Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: Primary ebulking surgery and interval debulking surgery for advanced ovarian cancer","volume":"21","author":"Makar","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"18","author":"Muggia","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015048.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/j.1582-4934.2009.00911.x","article-title":"Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression","volume":"14","author":"Napoletano","year":"2010","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0248|cit248","unstructured":"National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology, ovarian cancer including fallopian tube cancer and primary peritoneal cancer http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf 2020"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0249|cit249","unstructured":"National Institute for Health and Care Excellence Ultra-radical (extensive) surgery for advanced ovarian cancer. NICE Interventional procedure guidance [IPG 470] https:\/\/www.nice.org.uk\/guidance\/ipg470 2013"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jclinepi.2016.02.031","article-title":"Adequate sample size for developing prediction models is not simply related to events per variable","volume":"76","author":"Ogundimu","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"17","key":"10.1002\/14651858.CD015048.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015048.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/0008-5472.CAN-15-1382","article-title":"It's totally tubular. Riding the new wave of ovarian cancer research","volume":"76","author":"Perets","year":"2016","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1471-0528.1994.tb13080.x","article-title":"Intervention debulking surgery in advanced epithelial ovarian cancer","volume":"101","author":"Redman","year":"1994","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"International Journal of Gynecologic Cancer"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0256|cit256","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0258|cit258","doi-asserted-by":"publisher","DOI":"10.1017\/9781316986844","volume-title":"Gynaecological Oncology for the MRCOG","author":"Shafi","year":"2018"},{"issue":"28","key":"10.1002\/14651858.CD015048.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1200\/JCO.2006.10.3846","article-title":"Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Spriggs","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0260|cit260","unstructured":"Sterne JAC Egger M Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"750\u20135","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"issue":"7","key":"10.1002\/14651858.CD015048.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/1471-0528.17041","article-title":"Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study","volume":"129","author":"Sundar","year":"2022","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"34\u201343","DOI":"10.1111\/aogs.13453","article-title":"Impact of residual disease on overall survival in women with federation of gynecology and obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery","volume":"98","author":"S\u00f8rensen","year":"2019","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0264|cit264","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006014","article-title":"Interval debulking surgery for advanced epithelial ovarian cancer","author":"Tangjitgamol","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD015048.pub2-BIB0265|cit265","first-page":"284\u201396","article-title":"Ovarian cancer statistics","volume":"68","author":"Torre","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"10","key":"10.1002\/14651858.CD015048.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer co-operative group of the European organization for research and treatment of cancer","volume":"332","author":"Burg","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2012.09.013","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?","volume":"128","author":"Vergote","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0268|cit268","unstructured":"Vergote I Vlayen J Heus P Hoogendam JP Damen JA Van de Wetering FT Ovarian cancer: diagnosis, treatment and follow-up; KCE Report 28Cs; 2016 Available at: kce.fgov.be\/sites\/default\/files\/atoms\/files\/KCE_268Cs_Ovarian_cancer_summary.pdf 2016"},{"key":"10.1002\/14651858.CD015048.pub2-BIB0269|cit269","first-page":"3","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Clinical Obstetrics & Gynaecology"},{"issue":"8","key":"10.1002\/14651858.CD015048.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015048.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015048.pub2-BIB0272|cit272","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007945.pub2","article-title":"Centralisation of services for gynaecological cancer","author":"Woo","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:05:01Z","timestamp":1733756701000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015048.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":272,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015048.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}